Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 5Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Genitourinary 3Sarcoma 2Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1

Interventions

Standard of Care 4Radiotherapy 4Oxaliplatin 4tislelizumab 3anlotinib 2Radiation 2Paclitaxel 2Capecitabine 2130-nm albumin-bound paclitaxel 2vedolizumab 1trastuzumab deruxtecan 1trametinib 1toripalimab 1surufatinib 1pembrolizumab 1ivosidenib 1disitamab vedotin 1coenzyme Q10 1cemiplimab 1blinatumomab 1Whole Genome Sequencing 1Ursodeoxycholic Acid 1Ultrasonography 1Tretinoin 1Thymopentin 1Surgical Procedures, Operative 1Sequence Analysis, RNA 1Respiratory Rate 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prednisone × Tumor-Agnostic × Clear all
NCT06099990 2023-10-25

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Not yet recruiting
660 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡